MX2014002693A - Uso de 1h-quinazolina-2,4-dionas para usarse en la prevencion o el tratamiento de epilepsia fotosensible. - Google Patents

Uso de 1h-quinazolina-2,4-dionas para usarse en la prevencion o el tratamiento de epilepsia fotosensible.

Info

Publication number
MX2014002693A
MX2014002693A MX2014002693A MX2014002693A MX2014002693A MX 2014002693 A MX2014002693 A MX 2014002693A MX 2014002693 A MX2014002693 A MX 2014002693A MX 2014002693 A MX2014002693 A MX 2014002693A MX 2014002693 A MX2014002693 A MX 2014002693A
Authority
MX
Mexico
Prior art keywords
prevention
diones
quinazoline
photosensitive epilepsy
treatment
Prior art date
Application number
MX2014002693A
Other languages
English (en)
Spanish (es)
Inventor
Donald Johns
Klaus Kucher
George Imbert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2014002693A publication Critical patent/MX2014002693A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014002693A 2011-09-07 2011-09-07 Uso de 1h-quinazolina-2,4-dionas para usarse en la prevencion o el tratamiento de epilepsia fotosensible. MX2014002693A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/050687 WO2013036224A1 (en) 2011-09-07 2011-09-07 Use of 1h-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy

Publications (1)

Publication Number Publication Date
MX2014002693A true MX2014002693A (es) 2014-06-04

Family

ID=44652020

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002693A MX2014002693A (es) 2011-09-07 2011-09-07 Uso de 1h-quinazolina-2,4-dionas para usarse en la prevencion o el tratamiento de epilepsia fotosensible.

Country Status (10)

Country Link
EP (1) EP2753331A1 (de)
JP (1) JP2014525474A (de)
KR (1) KR20140071405A (de)
CN (1) CN103889427A (de)
AU (1) AU2011376333A1 (de)
BR (1) BR112014005210A2 (de)
CA (1) CA2846503A1 (de)
IN (1) IN2014DN01791A (de)
MX (1) MX2014002693A (de)
WO (1) WO2013036224A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
AU2016381366A1 (en) 2015-12-30 2018-06-28 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0201943D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab New use
CA2549965A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes iii
EP1677789A1 (de) 2003-10-31 2006-07-12 AstraZeneca AB Alkyne i
JP2007509935A (ja) 2003-10-31 2007-04-19 アストラゼネカ アクチボラグ アルキンズｉｉ
WO2005079802A1 (en) 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
AU2006329007A1 (en) 2005-12-20 2007-06-28 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
WO2011055385A1 (en) * 2009-11-03 2011-05-12 Lupin Limited Modified release formulation of lacosamide

Also Published As

Publication number Publication date
EP2753331A1 (de) 2014-07-16
AU2011376333A1 (en) 2014-03-13
CN103889427A (zh) 2014-06-25
WO2013036224A1 (en) 2013-03-14
IN2014DN01791A (de) 2015-05-15
KR20140071405A (ko) 2014-06-11
BR112014005210A2 (pt) 2017-03-21
JP2014525474A (ja) 2014-09-29
CA2846503A1 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
HUS2000032I1 (hu) Helyettesített 4-fenil-piridinek NK-1 receptorral kapcsolatos betegségek kezelésére
GB201017345D0 (en) Receptor antagonists
UA116196C2 (uk) Синтетичний міметик апеліну для лікування серцевої недостатності
MX367341B (es) Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
MX355543B (es) Macrociclos peptidomiméticos.
WO2012173846A3 (en) Peptidomimetic macrocycles
JO3300B1 (ar) مركبات وتركيبات لتعديل نشاط egfr
MX360710B (es) Antagonistas de il17c para el tratamiento de trastornos inflamatorios.
MX340259B (es) Formulaciones de testosterona.
MX2014011104A (es) Moduladores del receptor x del higado.
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
IN2014CN04014A (de)
MX354818B (es) Moduladores del receptor x del higado.
CL2013002908A1 (es) Uso de compuestos derivados de bencimidazol-4-carboxamida para el tratamiento profilactico de la neuropatia periferica inducida por quimioterapia .
PH12018500282A1 (en) Cgrp receptor antagonists
HK1201729A1 (zh) -抑制劑在治療中樞神經系統繼發性水腫中的應用
HK1204325A1 (en) Phragamalin limonoids for the treatment of sexual dysfunction phragmalin
IN2014DN00254A (de)
HUE045270T2 (hu) FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
MY165088A (en) Pharmaceutical compositions comprising alisporivir
GEP201706636B (en) Galactagogue compositions based on phosphatidylserine
MX2014002693A (es) Uso de 1h-quinazolina-2,4-dionas para usarse en la prevencion o el tratamiento de epilepsia fotosensible.
GB201012359D0 (en) Invention 6.5.10
SG11202111525XA (en) Stable targeted integration
IN2012DN01846A (de)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal